 This study will assess the safety and efficacy of adding nateglinide to treatment with basal insulin glargine, metformin andor thiazolidinedione pioglitazone or rosiglitazone, for patients with type 2 diabetes who are not achieving glycemic control with glargine, metformin andor thiazolidinedione only. 